Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ENTA 01.08.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2024-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur ENTA Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.08.2025 - Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.24.2024 - Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Recent Filings

  • 01.22.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.09.2024 - EX-99.1 EX-99.1
PDF Version

WATERTOWN, Mass.--(BUSINESS WIRE)--Jan. 8, 2025--Enanta Pharmaceuticals, Inc.(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced thatJay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rdAnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 15, 2024at8:15 a.m. PTinSan Francisco, CA.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website atwww.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

AboutEnanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visitwww.enanta.comfor more information.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250108518953/en/

Media and Investors Contact:Jennifer Viera617-744-3848jviera@enanta.com

Source:Enanta Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com